Better late than early: FDG-PET imaging in metastatic renal cell carcinoma

Clin Cancer Res. 2011 Sep 15;17(18):5841-3. doi: 10.1158/1078-0432.CCR-11-1768.

Abstract

Sunitinib treatment benefits patients with metastatic renal cell carcinoma (mRCC), but response duration can vary widely and resistance is not predicted by standard measures. [¹⁸F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) uptake is variable in mRCC, but changes in FDG-PET uptake may be useful in monitoring disease progression. Further work is needed to personalize treatment for patients with mRCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Renal Cell / diagnostic imaging*
  • Carcinoma, Renal Cell / pathology*
  • Fluorodeoxyglucose F18*
  • Humans
  • Kidney Neoplasms / diagnostic imaging*
  • Kidney Neoplasms / pathology*
  • Neoplasm Metastasis
  • Positron-Emission Tomography*
  • Radiopharmaceuticals*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18